Angioedema Market

 Market Overview:

The 7 major angioedema markets are expected to exhibit a CAGR of 6.99% during 2024-2034.

The angioedema market has been comprehensively analyzed in IMARC's new report titled "Angioedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Angioedema refers to a medical condition characterized by swelling beneath the skin, typically affecting the deeper layers of the skin and the mucous linings. This illness causes an accumulation of fluid in the denser regions of the skin, resulting in sudden and pronounced inflammation. The ailment commonly affects various areas, such as the face, lips, tongue, throat, hands, feet, genitals, etc. The symptoms of the disease develop rapidly and may last for a few hours to several days. Some common indications associated with the disorder include swelling, pain, or discomfort in the affected areas, itching, skin discoloration, etc. In cases where angioedema occurs in the throat or tongue, it can lead to voice changes, difficulty breathing, and trouble speaking or swallowing. The diagnosis of this condition involves a thorough medical history evaluation, clinical feature assessments, and physical examination findings. A healthcare provider may further recommend several investigations, including allergy testing, skin prick tests, blood workups, etc., to identify any specific triggers that could be related to the underlying cause of the disease.

The increasing cases of exposure to allergens, such as certain foods (e.g., nuts, shellfish, eggs, etc.), nonsteroidal anti-inflammatory drugs, insect stings, latex, etc., which release histamine into the bloodstream, are primarily driving the angioedema market. In addition to this, the rising prevalence of genetic disorders causing a deficiency or dysfunction of a protein involved in regulating the immune response is creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, including antihistamines, corticosteroids, epinephrine, etc., to alleviate discomfort and manage acute episodes of the disease is further bolstering the market growth. Apart from this, the escalating utilization of cryocompression therapy, since it involves the application of cold temperatures and pressure to a specific area of the body to control pain, swelling, and inflammation, as well as to promote healing and recovery, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immune-modulatory drugs, which help to minimize the frequency and severity of attacks and boost the overall quality of life, is expected to drive the angioedema market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the angioedema market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for angioedema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the angioedema market in any manner.

Recent Developments:

• In June 2024, Ionis Pharmaceuticals, Inc. announced that it had entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka), under which Otsuka will be granted exclusive rights to donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE), in the Asia-Pacific region. Donidalorsen will be developed primarily by Ionis, with Otsuka in charge of territory-specific development, regulatory filings, and commercialization in Asia-Pacific and Europe.
• In June 2024, KalVista Pharmaceuticals announced that it had submitted a New Drug Application (NDA) for the FDA to review sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE attacks in adults and pediatric patients aged 12 and above.

Key Highlights

• The World Allergy Organization (WAO) reports that urticaria and angioedema impact up to 20% of the population.
• It is anticipated that roughly 10-20% of the population may experience at least one episode of angioedema over their lives.
• Approximately 40-50% of patients with chronic spontaneous urticaria have angioedema, and about 10% have angioedema only.
• Chronic or recurrent angioedema affects approximately 0.5% of the population.
• The rate of hospital admissions for angioedema is increasing steadily (3.0% per year).
• The rate of hospitalization is higher in people aged 65 and older.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the angioedema market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the angioedema market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current angioedema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the angioedema market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the angioedema market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the angioedema market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of angioedema across the seven major markets?
• What is the number of prevalent cases (2018-2034) of angioedema by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of angioedema by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with angioedema across the seven major markets?
• What is the size of the angioedema patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of angioedema?
• What will be the growth rate of patients across the seven major markets?
   

Angioedema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for angioedema drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the angioedema market?
• What are the key regulatory events related to the angioedema market?
• What is the structure of clinical trial landscape by status related to the angioedema market?
• What is the structure of clinical trial landscape by phase related to the angioedema market?
• What is the structure of clinical trial landscape by route of administration related to the angioedema market?